BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Talks.cam//talks.cam.ac.uk//
X-WR-CALNAME:Talks.cam
BEGIN:VEVENT
SUMMARY:The neonatal Fc receptor (FcRn) – not just for kids!  - Jan Terj
 e Andersen University of Oslo Centre for Immune Regulation
DTSTART:20130606T153000Z
DTEND:20130606T163000Z
UID:TALK45718@talks.cam.ac.uk
CONTACT:Dr Tennie Videler
DESCRIPTION:Albumin is the most abundant protein in blood and fulfills ess
 ential roles in distribution and transport of an array of compounds such a
 s nutrients\, metabolites\, hormones\, drugs and toxins. It shares a long 
 serum half-life of three weeks with the IgG class of antibodies. The long 
 half-life has made IgG the preferred choice for antibody-based therapeutic
 s\, while albumin is utilized as fusion partner for small protein therapeu
 tics. Surprisingly\, a common molecular mechanism extends the half-life of
  both\, as they are rescued from degradation by a single receptor\, named 
 the neonatal Fc receptor (FcRn)\, expressed in endothelial cells lining th
 e blood vessels and hematopoietic cells.\nBeside its role as a homeostatic
  regulator\, FcRn has also been found to be a versatile receptor with seve
 ral important functions at different body sites\, as for instance transpor
 t of IgG across mucosal surfaces and from mother to fetus across placenta\
 , as well as enhancement of antigen presentation and cross-presentation in
  dendritic cells. Hence\, increasing appreciation of the unique roles of F
 cRn as a multiplayer in immune regulation has triggered intense interest f
 rom both academia and biotech companies. Here\, I will summarize our curre
 nt cellular and molecular understanding of FcRn biology and demonstrate ho
 w ligand interaction with FcRn can be manipulated for improved therapeutic
  efficacy.  \n
LOCATION:MPLT\, MRC-LMB\, Francis Crick Avenue\, Cambridge Biomedical Camp
 us\, CB2 0QH
END:VEVENT
END:VCALENDAR